TD Cowen Forecasts Strong Price Appreciation for Addus HomeCare (NASDAQ:ADUS) Stock

Addus HomeCare (NASDAQ:ADUS) had its price target raised by stock analysts at TD Cowen from $131.00 to $145.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s price target would suggest a potential upside of 16.64% from the company’s previous close.

Several other equities research analysts also recently issued reports on the company. Royal Bank Of Canada raised their price target on Addus HomeCare from $130.00 to $134.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Citigroup cut Addus HomeCare from a “market outperform” rating to a “neutral” rating in a research report on Monday, September 14th. Barclays raised their target price on Addus HomeCare from $96.00 to $101.00 and gave the company an “underweight” rating in a report on Wednesday. Truist Financial upped their price target on Addus HomeCare from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Weiss Ratings upgraded shares of Addus HomeCare from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $134.70.

Addus HomeCare Stock Performance

Shares of NASDAQ ADUS traded down $2.50 during trading hours on Thursday, hitting $124.31. 276,627 shares of the stock were exchanged, compared to its average volume of 212,662. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.69 and a quick ratio of 1.69. The company’s 50 day moving average is $117.60 and its 200 day moving average is $106.88. The firm has a market capitalization of $2.32 billion, a P/E ratio of 20.72, a P/E/G ratio of 1.79 and a beta of 0.75. Addus HomeCare has a one year low of $87.95 and a one year high of $131.59.

Addus HomeCare (NASDAQ:ADUS) last announced its earnings results on Tuesday, November 3rd. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.79 by $0.04. The firm had revenue of $387.74 million for the quarter, compared to the consensus estimate of $388.72 million. Addus HomeCare had a net margin of 7.13% and a return on equity of 9.96%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.56 EPS. On average, research analysts expect that Addus HomeCare will post 6.34 EPS for the current year.

Hedge Funds Weigh In On Addus HomeCare

Several institutional investors have recently added to or reduced their stakes in ADUS. BlackRock Inc. acquired a new position in Addus HomeCare in the second quarter valued at about $344,153,000. Dimensional Fund Advisors LP increased its holdings in shares of Addus HomeCare by 11.8% during the first quarter. Dimensional Fund Advisors LP now owns 744,127 shares of the company’s stock worth $69,689,000 after buying an additional 78,415 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Addus HomeCare during the second quarter worth approximately $35,527,000. TimesSquare Capital Management LLC acquired a new stake in shares of Addus HomeCare during the second quarter worth approximately $31,502,000. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Addus HomeCare by 110.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 189,718 shares of the company’s stock valued at $21,192,000 after acquiring an additional 99,596 shares during the last quarter. 95.35% of the stock is owned by institutional investors.

Addus HomeCare News Summary

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: UBS raised its price target to $160 from $145 and maintained a Buy rating; TD Cowen lifted its target to $145 from $131 and also maintained a Buy rating. UBS price-target report TD Cowen price-target report
• Positive Sentiment: ADUS recently reached a 52-week high. Its latest quarterly results included earnings per share of $1.83, ahead of the $1.79 consensus, while revenue increased 7% year over year. Addus hits a 12-month high
• Positive Sentiment: The company said it expects to close its AccentCare acquisition in the first quarter of 2027 and anticipates a full-year adjusted EBITDA margin around 13%; the deal may offer a growth opportunity, though execution remains ahead. AccentCare update
• Neutral Sentiment: Recent Zacks pieces discuss ADUS’s momentum and value-investing appeal, but the available summaries do not provide specific ratings or new estimates. Zacks momentum article Zacks value article
• Negative Sentiment: Quarterly revenue of $387.74 million was slightly below analysts’ $388.72 million estimate, tempering the otherwise positive earnings beat. Q3 earnings call highlights

About Addus HomeCare

Addus HomeCare Inc (NASDAQ: ADUS) provides in-home personal care, hospice and home health services to older adults, people with disabilities and other individuals who need assistance with daily living or medical care. Its services are designed to help clients remain safely and independently in their homes while supporting families and caregivers.

The company’s personal care services include assistance with bathing, dressing, grooming, meal preparation, housekeeping and other activities of daily living.